Cabot (CBT) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
23 Nov, 2025Executive summary
Q3 FY25 Adjusted EPS was $1.90, down 1% year-over-year; diluted EPS was $1.86, reflecting strong execution amid an 8% volume decline due to macroeconomic headwinds and tariffs.
Reinforcement Materials EBIT declined 6% to $128M, while Performance Chemicals EBIT rose 4% to $57M.
$64M was returned to shareholders via dividends and share repurchases in Q3.
Announced acquisition of Bridgestone's reinforcing carbons plant in Mexico for $70M, expected to close in H1 fiscal 2026 and be accretive in year one.
Achieved a fifth consecutive Platinum EcoVadis sustainability rating, ranking in the top 1% of basic chemical manufacturers globally.
Financial highlights
Q3 FY25 net sales were $923M, down from $1,016M year-over-year, mainly due to lower volumes and less favorable pricing.
Operating cash flow for Q3 FY25 was $249M; free cash flow was $188M after $61M in capital expenditures.
Cash and cash equivalents at quarter-end were $239M; liquidity at $1.4B; net debt to EBITDA ratio at 1.3x.
Dividend increased by 5% in May; $24M paid in dividends and $40M in share repurchases during Q3.
Gross profit for Q3 FY25 was $244M, down from $256M year-over-year.
Outlook and guidance
Full-year FY25 Adjusted EPS guidance reaffirmed at $7.15–$7.50, with Q4 segment EBIT expected to be consistent with the prior year.
FY25 capex guidance is $250M–$275M; share repurchases expected to be $150M–$200M.
Operating tax rate for FY25 projected at 27%–29%.
If recent tariff actions boost demand, results could trend toward the higher end of guidance.
Sufficient liquidity is anticipated for operational and capital needs for the next twelve months and foreseeable future.
Latest events from Cabot
- Adjusted EPS down 13% to $1.53; Battery Materials up 39%, Reinforcement Materials EBIT down 22%.CBT
Q1 20264 Feb 2026 - Q3 adjusted EPS up 35% year-over-year; FY2024 guidance raised on strong segment growth.CBT
Q3 20242 Feb 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor ratification.CBT
Proxy Filing27 Jan 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong ESG focus.CBT
Proxy Filing27 Jan 2026 - 31% EPS growth, $265M returned to shareholders, and 2025 EPS guidance of $7.40–$7.80.CBT
Q4 202416 Jan 2026 - FY24 adjusted EPS guidance raised to $7.00–$7.10, driven by battery, E2C, and inkjet growth.CBT
Investor Day 202412 Jan 2026 - Adjusted EPS up 13% to $1.76; net income and cash flow drive strong shareholder returns.CBT
Q1 20259 Jan 2026 - Annual meeting to vote on directors, executive pay, new incentive plan, and auditor ratification.CBT
Proxy Filing1 Dec 2025 - Key votes include director elections, executive pay, incentive plan, and auditor ratification.CBT
Proxy Filing1 Dec 2025